Cargando…
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma
SIMPLE SUMMARY: Out of all the skin cancers, melanoma is the most aggressive and dangerous form due to its high metastatic propensity. Patients with late-stage melanomas have poor prognosis as their five-year survival rate is only 27% while the survival rate for primary melanomas is 99%. Metastatic...
Autores principales: | Eddy, Kevinn, Chen, Suzie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345431/ https://www.ncbi.nlm.nih.gov/pubmed/34359771 http://dx.doi.org/10.3390/cancers13153874 |
Ejemplares similares
-
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
por: Eddy, Kevinn, et al.
Publicado: (2021) -
Overcoming Immune Evasion in Melanoma
por: Eddy, Kevinn, et al.
Publicado: (2020) -
Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma
por: Isola, Allison L., et al.
Publicado: (2016) -
Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness
por: Isola, Allison L., et al.
Publicado: (2017) -
Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression()()
por: Rosenberg, Stephen A., et al.
Publicado: (2015)